ACRS
Aclaris Therapeutics, Inc.Company with tickers: ACRS
CIK
1557746
CUSIP
00461U105
Shares Outstanding
139,663,680
13F Activity (30d)
92 filings
89 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $1,996,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Cost of Revenue | $395,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $15,657,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $-22,192,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $-19,824,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | $-0.15 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Diluted) | $-0.15 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |